Role of leptin in obesity, cardiovascular disease, and Type 2 diabetes

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Vilariño-García, Teresa
• dc.contributor.author Polonio-González, María L.
• dc.contributor.author Pérez Pérez, Antonio
• dc.contributor.author Ribalta, Josep
• dc.contributor.author Arrieta, Francisco
• dc.contributor.author Aguilar, Manuel
• dc.contributor.author Obaya, Juan C.
• dc.contributor.author Gimeno-Orna, José A.
• dc.contributor.author Iglesias, Pedro
• dc.contributor.author Navarro, Jorge
• dc.contributor.author Durán, Santiago
• dc.contributor.author Pedro-Botet, Juan Carlos
• dc.contributor.author Sánchez-Margalet, Víctor
• dc.date.accessioned 2025-04-04T06:15:22Z
• dc.date.available 2025-04-04T06:15:22Z
• dc.date.issued 2024
• dc.description.abstract Diabetes mellitus (DM) is a highly prevalent disease worldwide, estimated to affect 1 in every 11 adults; among them, 90-95% of cases are type 2 diabetes mellitus. This is partly attributed to the surge in the prevalence of obesity, which has reached epidemic proportions since 2008. In these patients, cardiovascular (CV) risk stands as the primary cause of morbidity and mortality, placing a substantial burden on healthcare systems due to the potential for macrovascular and microvascular complications. In this context, leptin, an adipocyte-derived hormone, plays a fundamental role. This hormone is essential for regulating the cellular metabolism and energy balance, controlling inflammatory responses, and maintaining CV system homeostasis. Thus, leptin resistance not only contributes to weight gain but may also lead to increased cardiac inflammation, greater fibrosis, hypertension, and impairment of the cardiac metabolism. Understanding the relationship between leptin resistance and CV risk in obese individuals with type 2 DM (T2DM) could improve the management and prevention of this complication. Therefore, in this narrative review, we will discuss the evidence linking leptin with the presence, severity, and/or prognosis of obesity and T2DM regarding CV disease, aiming to shed light on the potential implications for better management and preventive strategies.
• dc.format.mimetype application/pdf
• dc.identifier.citation Vilariño-García T, Polonio-González ML, Pérez-Pérez A, Ribalta J, Arrieta F, Aguilar M, et al. Role of leptin in obesity, cardiovascular disease, and Type 2 diabetes. Int J Mol Sci. 2024 Feb 16;25(4):2338. DOI: 10.3390/ijms25042338
• dc.identifier.doi http://dx.doi.org/10.3390/ijms25042338
• dc.identifier.issn 1422-0067
• dc.identifier.uri http://hdl.handle.net/10230/70091
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Int J Mol Sci. 2024 Feb 16;25(4):2338
• dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Cardiovascular risk
• dc.subject.keyword Inflammation
• dc.subject.keyword Leptin
• dc.subject.keyword Obesity
• dc.subject.keyword Type 2 diabetes mellitus
• dc.title Role of leptin in obesity, cardiovascular disease, and Type 2 diabetes
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion